Dense fine speckled nuclear immunofluorescence: A mildly reassuring antinuclear antibody pattern meriting consideration
- PMID: 37773695
- PMCID: PMC10521372
- DOI: 10.1002/iid3.1026
Dense fine speckled nuclear immunofluorescence: A mildly reassuring antinuclear antibody pattern meriting consideration
Abstract
Introduction: Antinuclear antibodies (ANAs) are regarded as a hallmark of connective tissue diseases (CTDs) and play a key role in their diagnosis, but the value of some particular antibodies in management of patients and the disease prognosis is controversial. The mechanism underlying the production of ANAs in CTDs, other chronic inflammatory conditions and even in healthy people, is not completely elucidated. Anti-DFS70 antibodies connected with the dense fine speckled autoantigen of 70 kD, known as the lens epithelium-derived growth factor p75, are a subgroup of ANAs. Their presence and coexistence with other antibodies and their clinical significance are the matter of debate.
Methods: Based on literature data, the authors focused on current knowledge explaining the role of anti-DFS70 antibodies in selected CTDs.
Results: However, the literature data is ambiguous and does not fully support the validity of the anti-DFS70 assay for a specific CTD diagnosis. Most researchers claim that the presence of anti-DFS70 as the only one usually exclude the diagnosis of CTD. Nevertheless, its coexistence with other ANAs is not an excluding factor but has predictive value due to more favorable course of CTD. Such situations may also suggest an enhanced risk of the development of a CTD in the future.
Conclusions: Although more studies are needed in this field, it seems reasonable to ascertain the presence of anti-DFS70 in routine clinical practice.
Keywords: Sjögren's syndrome; anti-DFS70 antibody assay; antinuclear antibodies; connective tissue diseases; systemic lupus erythematosus; systemic sclerosis.
© 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Autoantibodies to dense-fine-speckled 70 (DFS70) do not necessarily rule out connective tissue diseases.Semin Arthritis Rheum. 2022 Feb;52:151936. doi: 10.1016/j.semarthrit.2021.12.006. Epub 2021 Dec 30. Semin Arthritis Rheum. 2022. PMID: 35027246
-
Application of anti-DFS70 antibody and specific autoantibody test algorithms to patients with the dense fine speckled pattern on HEp-2 cells.Scand J Rheumatol. 2016;45(2):122-8. doi: 10.3109/03009742.2015.1060260. Epub 2015 Dec 7. Scand J Rheumatol. 2016. PMID: 26643611
-
Clinical use of anti-DFS70 autoantibodies.Rheumatol Int. 2019 Aug;39(8):1423-1429. doi: 10.1007/s00296-019-04299-4. Epub 2019 Apr 10. Rheumatol Int. 2019. PMID: 30972541
-
Autoantibodies Against DFS70/LEDGF Exclusion Markers for Systemic Autoimmune Rheumatic Diseases (SARD).Clin Lab. 2016;62(4):499-517. doi: 10.7754/clin.lab.2015.150905. Clin Lab. 2016. PMID: 27215068 Review.
-
Twenty years of research on the DFS70/LEDGF autoantibody-autoantigen system: many lessons learned but still many questions.Auto Immun Highlights. 2020 Feb 3;11(1):3. doi: 10.1186/s13317-020-0126-4. Auto Immun Highlights. 2020. PMID: 32127038 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials